137 results on '"Satzger I"'
Search Results
2. Remission eines iatrogenen Kaposi-Sarkoms bei Myasthenia gravis nach Umstellung der Immunsuppression auf den mTOR-Inhibitor Everolimus
3. Sentinel Node Dissection Delays Recurrence and Prolongs Melanoma-Related Survival: An Analysis of 673 Patients from a Single Center with Long-Term Follow-Up
4. Schildwächterlymphknotenbiopsie beim Melanom
5. Allele frequencies of BRAFV600E mutations are not correlated with treatment outcome in 76 metastatic melanoma patients: FV12
6. Impaired NLRP3 inflammasome expression and function in atopic dermatitis due to Th2 milieu
7. Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma
8. Intravaskuläre B-Zell-Lymphome: Ein heterogenes Krankheitsbild, dargestellt an 2 Patienten
9. Real World-Daten zur Anwendung von Nivolumab (Nivo) als Monotherapie oder in Kombination mit Ipilimumab (Nivo+Ipi) in der Behandlung des fortgeschrittenen Melanoms: Zwischenergebnisse der nicht-interventionellen Studie NICO [Poster Abstract]
10. Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (Nature Medicine, (2019), 25, 12, (1916-1927), 10.1038/s41591-019-0654-5)
11. Are metastatic pathways and the time of progression altered by sentinel node excision?: FV26
12. Relevance of the mTOR Signaling Pathway in Cutaneous Squamous Cell Carcinoma - An Immunohistochemical Study of 58 Immunocompetent and Organ Transplanted Patients: FC-066
13. BRAFV600 Mutations are Highly Consistent in Primary Melanomas and Matched Metastases- an Analysis of 160 Paired Tissue Samples by Real Time PCR and Next-Generation Sequencing: FC-010
14. The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network: FV04/07
15. Die Rolle des m-TOR Signalweges bei kutanen Plattenepithelkarzinomen: FV03/06
16. Die radikale Lymphknotendissektion hat keinen Einfluß auf die Prognose bei Melanompatienten mit geringer Tumorlast im Sentinel-Lymphknoten- eine retrospektive Analyse von 305 Patienten: FV-064
17. Nicht-melanozytäre Hauttumoren treten nach Umstellung der Immunsuppression auf mTor-Inhibitoren seltener auf - eine Fallserie von 12 organtransplantierten Patienten: FV-043
18. 1104P Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO
19. Welche Klassifikation des Sentinelbefalls kann die Prognose von Melanompatienten am besten einschätzen?: FV9
20. Analysis of C-KIT expression and KIT gene mutation in human mucosal melanomas: FV15
21. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients
22. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
23. Erstbeschreibung eines hämatogen-allergischen Kontaktekzems (Baboon) auf Ciclesonid und andere parenterale Kortikosteroide vom Triamcinolontyp: V8
24. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients
25. Criteria in sentinel nodes of melanoma patients that predict involvement of non-sentinel nodes - Is H&E staining sufficient? (Completion lymphadenectomy is only mandatory for patients with sentinel lymph nodes positive by H&E staining): P21/21
26. Das Auftreten von Autoimmunerkrankungen unter adjuvanter Therapie mit Niedrigdosis-Interferon alpha ist assoziiert mit einer besseren Prognose bei Melanompatienten: P21/22
27. NICO ‐ eine nationale, prospektive, nicht‐interventionelle Studie (NIS) mit Nivolumab als Monotherapie oder in Kombination mit Ipilimumab bei Patienten mit fortgeschrittenem (inoperablem oder metastasiertem) Melanom zur Erhebung von real‐world data
28. Charakterisierung des Checkpoint‐Inhibitor‐assoziierten Diabetes mellitus – Erfahrungen bei 12 Patienten
29. Kombination von Denosumab und einer Immuntherapie mit PD‐1‐Inhibitoren – eine retrospektive Analyse von 29 Patienten mit metastasiertem malignen Melanom und Knochenmetastasen
30. The pattern and clinicopathological correlates of programmed death-ligand 1 expression in cutaneous squamous cell carcinoma
31. Treatment of Advanced Cutaneous Squamous Cell Carcinomas with Epidermal Growth Factor Receptor Inhibitors
32. P073. Dermatological follow-up of patients with non melanoma skin cancer after solid organ transplantation switched to an mTOR inhibitor
33. Sentinel Node Dissection Delays Recurrence and Prolongs Melanoma-Related Survival: An Analysis of 673 Patients from a Single Center with Long-Term Follow-Up
34. P90 Remission of iatrogenic Kaposi's sarcoma after switch of immunosuppressive regimen to everolimus in a patient with myasthenia gravis
35. P25 Prognostic value of SLN biopsy in malignant melanoma of the head/neck in comparison to trunk and extremities
36. Comparison of classification systems in melanoma sentinel nodes: An analysis of 697 patients from a single center.
37. Does Basal Cell Carcinoma Belong to the Spectrum of Sorafenib-Induced Epithelial Skin Cancers?
38. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas
39. Intravaskuläre B-Zell-Lymphome
40. Evaluation of criteria in sentinel nodes of melanoma patients that predict involvement of non-sentinel nodes
41. Treatment of Advanced Cutaneous Squamous Cell Carcinomas with Epidermal Growth Factor Receptor Inhibitors.
42. Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study.
43. Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy.
44. Erfolgreiche Behandlung eines metastasierenden Melanoms mit Talimogen laherparepvec (T-VEC) bei einer lebertransplantierten Patientin.
45. Successful treatment of a metastatic melanoma with Talimogen laherparepvec (T-VEC) in a liver transplant patient.
46. Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
47. Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden.
48. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
49. Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook.
50. Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.